SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility as investors react to the intensifying demand for AI-driven semiconductors, which has historically fueled a massive rally in South Korean memory giants like Samsung and SK Hynix. While the community is actively debating whether the recent sharp pullbacks represent a necessary cooling off period or a deeper structural risk, the discourse remains polarized between long-term bulls betting on continued HBM shortages and traders wary of the risks associated with 3x leveraged exposure.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending following the disclosure of a critical security vulnerability in its Orchard privacy pool that could have allowed for the creation of counterfeit tokens, sparking widespread panic selling and intense debate over the platform's long-term viability. While developers have implemented a patch, the community remains deeply divided, with many traders debating whether the risk of undetected coin issuance is a fatal flaw or a buying opportunity amidst the volatility.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is currently drawing significant community attention due to sharp price volatility linked to broader Bitcoin market movements and institutional accumulation, with investors heavily debating whether to hold for consistent monthly dividends or exit due to NAV decay. While some traders are aggressively adding to their positions during these dips, others remain skeptical about the ETF's long-term performance compared to spot Bitcoin products.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense community activity and volatility as speculative traders debate its viability compared to emerging meme coins within the Solana ecosystem. Investors are divided between those betting on a potential rebound and those labeling the asset a high-risk gamble.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors react to institutional accumulation and ongoing frustration with stagnant price action despite a strong product portfolio and positive revenue developments. The community is actively debating the impact of potential FDA leadership changes on regulatory hurdles for gene therapies, while monitoring the influence of heavy short interest and the lack of immediate buyout activity on the share price.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

The Grayscale Bitcoin Mini Trust ETF is trending as investors debate whether current market volatility and geopolitical tensions present a buying opportunity or a signal of deeper downside. Community discussion is heavily focused on the interplay between self-custody, institutional leverage, and broader macroeconomic factors impacting Bitcoin's role as a risk asset.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to reports of a potential multibillion-dollar equity offering aimed at funding massive AI infrastructure investments. The community remains deeply divided, with some viewing the potential dilution as a necessary step to stay competitive in the AI arms race, while others criticize the spending as wasteful and express frustration over the stock's inability to sustain upward momentum.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing community attention as traders debate its potential to decouple from broader crypto market trends and reclaim historical highs. While some investors view the asset as a resilient, lower-fee alternative to Bitcoin, others remain skeptical, fueling heated discussions regarding its utility, long-term viability, and overall performance.

Ciena Corp. is a network technology company, which engages in the provision of hardware, software, and services to network operators, as well as enabling enhanced network capacity, service delivery, and automation. It operates through the following segments: Networking Platforms, Platform Software and Services, Blue Planet Automation Software and Services, and Global Services. The Networking Platforms segment consists of converged packet optical and packet networking portfolios. The Platform Software and Services segment provides analytics, data, and planning tools to assist customers in managing its networking platforms products. The Blue Planet Automation Software and Services segment enables customers to implement large-scale software and IT-led OSS transformations by transforming legacy networks into service ready networks. The Global Services segment offers a broad suite of value-added services. The company was founded by Patrick H. Nettles and Kevin Brian Kimberlin in 1992 and is headquartered in Hanover, MD.

CIENA Corp.

Ciena is trending as investors aggressively rotate capital into the optical networking infrastructure sector, viewing the company as a foundational backbone for scaling AI data centers. The community is actively discussing the stock's resilient upward momentum and its strategic positioning in the evolving optical stack, with many participants highlighting its strength as a critical long-term play for hyperscale connectivity.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is gaining momentum as investors pivot toward healthcare, fueled by the company's expanding insurance coverage for BetterHelp and a growing narrative around its AI-integrated global health platform. The stock is currently a major focus for traders watching a significant short interest position, while community discussions highlight potential upside from institutional accumulation and the stock's role as a long-term play in the digital healthcare space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences (AVXL) to Release Earnings on Tuesday

Anavex Life Sciences (NASDAQ:AVXL) will be releasing its Q2 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-12-anavex-life-sciences-corp-stock...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Receives Consensus Rating of "Hold" from Analysts

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) have received an average recommendation of 'Hold' from the five brokerages that are currently covering the firm, Marketbeat...

Anavex Life Sciences (NASDAQ:AVXL) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Anavex Life Sciences in a report on Monday. They set a 'buy' rating and a $20.00 target price on the stock...

Anavex Life Sciences (NASDAQ:AVXL) Share Price Passes Below 200 Day Moving Average - Time to Sell?

Anavex Life Sciences (NASDAQ:AVXL) Stock Passes Below Two Hundred Day Moving Average - Here's Why...

Anavex Life Sciences (NASDAQ:AVXL) Share Price Passes Below 200-Day Moving Average   - Time to Sell?

Anavex Life Sciences (NASDAQ:AVXL) Shares Cross Below Two Hundred Day Moving Average - Here's What Happened...

Anavex Life Sciences Teases New Pivotal Blarcamesine Trials, Maps Regulatory Path at Needham Conference

Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous...

Anavex Life Sciences' (AVXL) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued a "buy" rating and issued a $24.00 price target on shares of Anavex Life Sciences in a research note on Tuesday...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback

Anavex shares fall after pulling EU filing for blarcamesine in Alzheimer's; EMA feedback prompts more data work.read more...

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Equity

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Current Price	$2.57
Prev Close	$2.82
Open	$2.82
Dividend Yield	0.00%
50-Day Moving Average	$3.08
Beta	1.50
Avg. Volume	1.06M
PE Ratio	-5.53

52-Week High	$13.99
52-Week Low	$2.56
Market Capitalization	$261.33M
EPS (Annual)	-$0.5438
Price to Book	1.88
Revenue Per Employee	$0.00

AVXLAnavex Life Sciences Corp

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest AVXL News